These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital.
    Author: Fass RJ, Barnishan J, Ayers LW.
    Journal: J Antimicrob Chemother; 1995 Aug; 36(2):343-53. PubMed ID: 8522464.
    Abstract:
    We have continuously monitored the in-vitro activities of imipenem and ciprofloxacin against large numbers of non-fastidious clinical isolates. After eight years of use, 97-100% of Enterobacteriaceae and Acinetobacter baumannii remained susceptible to imipenem, but susceptibility of Pseudomonas aeruginosa declined from 100% to 91%. After six years of use, 94%-100% of Enterobacteriaceae (except Providencia stuartii) remained susceptible to ciprofloxacin but susceptibility of P. stuartii, A. baumannii and P. aeruginosa declined from 100% to 46%, 66% and 84%, respectively. Oxacillin-resistant staphylococci were considered to be resistant to imipenem and all beta-lactams. There were no quinolone-resistant staphylococci observed in 1986, but susceptibilities of Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus haemolyticus to ciprofloxacin decreased to 85-93% for oxacillin-susceptible strains and to 7-39% for oxacillin-resistant strains. Enterococcus faecalis has remained susceptible to imipenem and the modal MIC of ciprofloxacin has remained 1 mg/L; however, susceptibility to ciprofloxacin 2 mg/L decreased from 94% to 64%. Imipenem-quinolone cross-resistance was observed for staphylococci but not for P. aeruginosa.
    [Abstract] [Full Text] [Related] [New Search]